Last reviewed · How we verify
Bone
Bone drugs work by stimulating bone growth or reducing bone resorption.
Bone drugs work by stimulating bone growth or reducing bone resorption. Used for Treatment of osteoporosis, Treatment of glucocorticoid-induced osteoporosis.
At a glance
| Generic name | Bone |
|---|---|
| Sponsor | Ohio State University |
| Drug class | Bone anabolic agents |
| Modality | Biologic |
| Therapeutic area | Orthopedics |
| Phase | FDA-approved |
Mechanism of action
Bone drugs can either stimulate the activity of osteoblasts, the cells responsible for bone growth, or reduce the activity of osteoclasts, the cells responsible for bone resorption. This can help to increase bone density and reduce the risk of fractures.
Approved indications
- Treatment of osteoporosis
- Treatment of glucocorticoid-induced osteoporosis
Common side effects
- Bone pain
- Muscle weakness
- Osteopenia
Key clinical trials
- Assessment of Periprosthetic Bone Mineral Density in Patients Undergoing Total Knee Prosthesis of Different Design (NA)
- Immediate Restoration of a New Implant With High Primary Stability (NA)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm (PHASE2)
- Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML (PHASE1)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bone CI brief — competitive landscape report
- Bone updates RSS · CI watch RSS
- Ohio State University portfolio CI